Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA

Inclusion Criteria

• •Informed Consent: Prior to start any study related activities, participants must be able and willing to provide written informed consent;
• •Participants must have a current clinical diagnosis of asthma or EGPA;
• •Physician decision to initiate treatment with mepolizumab.
• •Patient has to be in treatment with medium-high dose ICS plus an additional controller in the least 6 months before screening and, if on OCS therapy, a stable dosage of prednisone (or equivalent dose of other steroids) in the 4 weeks before screening will be allowed. The above-indicated treatment has to be maintained by the patient all along the study.
• •Adults aged 18 years or over.